Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
4th January 2021
Portfolio
This post references, or is about Harpoon. Find out more by clicking below
Print Article
Email Article
Save Article
